Qiagen N.V. reported fourth‑quarter 2025 results that included net sales of $540.42 million, a 4% year‑over‑year increase and a 1% rise on a constant‑exchange‑rate basis. Adjusted diluted earnings per share were $0.62, matching the consensus estimate of $0.62 and falling short of the $0.60 outlook. The full‑year adjusted diluted EPS of $2.38 met the guidance of about $2.38 CER, while total revenue of $2.09 billion exceeded the consensus estimate of $527.96 million for the quarter.
The quarter’s performance was driven by a 7% constant‑exchange‑rate growth in the company’s core growth pillars, which generated $1.49 billion in CER sales and an 8% CER increase for the full year. Headwinds from the discontinuation of NeuMoDx and Dialunox products contributed a $10 million drag in Q4, while first‑time contributions from the Parse Biosciences acquisition added to the top line. The mix shift toward high‑margin consumables and disciplined cost control helped offset the legacy product exit.
Operating income margin for FY 2025 rose to 29.5%, an 80‑basis‑point improvement over 2024, reflecting the impact of discontinuing lower‑margin legacy lines and the higher mix of consumables. The company’s claim of maintaining a 30% operating‑margin floor is slightly overstated, as the actual margin was 29.5% for the year, but the trend toward a 30% floor remains evident.
Management reiterated its 2026 outlook, forecasting at least 5% constant‑exchange‑rate sales growth and a 9% contribution from growth pillars, with a combined sales target of approximately $1.64 billion. Full‑year EPS guidance remains around $2.38 CER, while Q1 2026 guidance projects revenue growth of at least 1% and adjusted EPS of at least $0.54, acknowledging acquisition costs and tariff impacts. CEO Thierry Bernard highlighted disciplined execution, the strength of the growth pillars, and the strategic value of AI and single‑cell capabilities, while CFO Roland Sackers emphasized shareholder returns and the integration of Genoox and Parse acquisitions.
Investor reaction to the earnings was muted, reflecting a cautious stance toward the Q1 2026 guidance and the costs associated with the Parse acquisition and tariff headwinds. The revenue beat of roughly 2.4% over consensus was offset by the fact that EPS met, rather than beat, expectations, leading to a tempered market response.
Qiagen remains on track to achieve its 2028 pillar‑sales target of $2 billion, with continued momentum in its high‑margin consumables and AI‑driven diagnostics. Near‑term challenges include tariff headwinds and the integration of new acquisitions, but the company’s disciplined cost management and focus on growth pillars position it well for sustained profitability.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.